2型糖尿病患者的血清维生素B12水平在美特福林治疗中的患者及其对周围神经传导的影响:前性研究
S L Wakode1, A Singhai, R Gour
1Professor Dr SL Wakode, Professor and Head, Department of Physiology, AIIMS, Bhopal, India.
Mymensingh medical journal : MMJ
|June 30, 2025
概括
对2型糖尿病的甲福明治疗可以降低维生素B12水平,可能会影响神经功能. 六个月的治疗显示维生素B12的减少和神经传导的改变,突出显示需要监测.
科学领域:
- 内分泌学和新陈代谢学
- 神经学 神经学
- 临床生理学 临床生理学
背景情况:
- 甲胺是2型糖尿病 (T2DM) 的第一线治疗方法.
- 甲胺使用与维生素B12缺乏有关,这可能导致或加剧神经病变.
- 甲胺,维生素B12水平和外周神经功能之间的相互作用需要进一步阐明.
研究的目的:
- 评估六个月的甲福明治疗对新诊断T2DM患者血清维生素B12水平的影响.
- 评估甲胺诱导的维生素B12变化对外围神经传导的影响.
- 为了研究维生素B12,同类半氨酸,甲基马龙酸和神经传导参数之间的相关性.
主要方法:
- 一项涉及52名新诊断T2DM患者的纵向研究.
- 神经传导研究 (运动和感觉) 在基线和六个月后进行.
- 血清维生素B12,homocysteine,甲基马龙酸,随机血糖和HbA1c在基线和六个月后被测量.
主要成果:
- 六个月的甲福明治疗显著降低了维生素B12水平 (p<0.001).
- 甲胺治疗导致血清同型半氨酸和甲基马龙酸水平显著增加 (p<0.001).
- 在运动神经和感官神经中观察到神经传导速度和振幅的显著减少.
结论:
- 在T2DM患者中,六个月的甲福明治疗显著降低了维生素B12水平.
- 虽然没有出现新的神经病变,但观察到神经传导参数的下降可能与维生素B12的减少有关.
- 建议对更大的队列和更长的随访进行进一步的研究,以充分了解长期影响.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
38
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
38
Diabetes: Management and Pharmacotherapy
409
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
409
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
Diabetes: Symptoms, Diagnosis, and Complications
706
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
706


